ストックスクリーナーアプリを入手
3.56
0.28%
-0.010
前日終値:
$3.57
開ける：
$3.5995
24時間の取引高:
10,391
Relative Volume:
0.06
時価総額：
$19.26M
収益：
$15.00M
当期純損益:
$2.71M
株価収益率:
2.7976
EPS:
1.2725
ネットキャッシュフロー:
$-2.89M
1週間 パフォーマンス:
-3.26%
1か月 パフォーマンス:
-5.32%
6か月 パフォーマンス:
-12.53%
1年 パフォーマンス:
-69.80%
1日の値動き範囲:
$3.53
$3.615
1週間の範囲:
$3.53
$3.6995
52週間の値動き範囲:
$3.19
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Compare NEUP vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
3.56 | 19.75M | 15.00M | 2.71M | -2.89M | 1.2725 |
VRTX
Vertex Pharmaceuticals Inc
|
522.81 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
758.27 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
192.57 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
958.91 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.26 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-09-28 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | 繰り返されました | Maxim Group | Buy |
| 2022-01-10 | 開始されました | Berenberg | Buy |
| 2022-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-01-10 | 開始されました | Evercore ISI | Outperform |
| 2022-01-10 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Neuphoria Therapeutics Inc (NEUP) 最新ニュース
MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership - stocktwits.com
Accenture, Abivax and 3 Stocks to Watch Heading Into Monday - Benzinga
Neuphoria to Be Acquired by Scancell in All-Stock Merger - Minichart
Neuphoria Therapeutics Q4 Results: EPS misses estimate, losses widen 76% - scanx.trade
Neuphoria Therapeutics Inc. FY 2026: Revenue $1.17M, Net loss $13.59M — 10-K Summary - TradingView
NEUP: FY26 saw a sharp revenue drop, major restructuring, and a $5.4M goodwill impairment amid a pending merger - TradingView
NEUP Stock Price and Chart — NASDAQ:NEUP - TradingView
Neuphoria Therapeutics Inc (NASDAQ: NEUP) Share Price, NEUP Stock News, NEUP Share Price & Updates - Kalkine
NEUP Q4'26 Earnings: EPS estimate is (0.56) USD - TradingView
Neuphoria (NEUP) EPS and Revenue: Reported EPS Tops Expectations for the Current Session; Share Move: Shares Move Lower 1.01% in the Available RecordGross Profit Margin - dars.gov.et
ACTU Stock Price and Chart — NASDAQ:ACTU - TradingView
Neuphoria Therapeutics Inc (NEUP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NEUP Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 90.9% EPS SurpriseGrowth Acceleration Report - careplusvn.com
Neuphoria Therapeutics (NEUP) Pulls Back to $3.82 as Traders Eye Key Support ZoneForce Index - dars.gov.et
Neuphoria Therapeutics (NEUP) Pulls Back 1.27% to $3.9, Holds Above Key SupportSocial Sentiment - vinanet.vn
Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders? - tradingview.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Neuphoria Therapeutics (NEUP) Slips to $3.88 as Bulls Defend Key SupportSector ETF Flow - dars.gov.et
NEUP Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Lean Cost ManagementEarnings Decline Risk - dars.gov.et
NEUP Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 90.9% EPS Surprise Amid Stock Pullback - careplusvn.com
Scancell merges with Nasdaq shell Neuphoria to fund USD 89m Phase III melanoma trial - allsci.com
Neuphoria Therapeutics (NEUP) Gains 3.55% as Stock Tests Key Resistance Near $4.14Retail Driven Moves - dars.gov.et
Advising Nasdaq-listed Neuphoria Therapeutics Inc. On Its USD250M Merger With AIM-listed Scancell Holdings - Mondaq
Melanoma Biotech Secures Nasdaq Listing via All-Share Merger - Streetwise Reports
Advising Nasdaq-listed Neuphoria Therapeutics Inc. on its USD250M merger with AIM-listed Scancell Holdings - Winston Taylor
Halper Sadeh LLC is Investigating Whether SAFT, NEUP, NRIM are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Neuphoria Therapeutics Inc (NEUP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NEUP|Neuphoria Therapeutics Inc|Price:3.970|Chg%:+0.330 - TradingKey
Neuphoria Therapeutics Inc (NEUP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuphoria Therapeutics Inc (NEUP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuphoria Therapeutics Inc (NEUP) Income Statement - tradingkey.com
Neuphoria Therapeutics (NEUP) Drops 7%: Key Levels in Focus After Sharp DeclineFibonacci Time Zone - po-news-eg.net
Neuphoria Therapeutics Inc. Revenue Breakdown – NASDAQ:NEUP - TradingView
NEUP|Neuphoria Therapeutics Inc|Price:3.810|Chg%:+0.170 - TradingKey
Neuphoria Therapeutics Inc (NEUP) Cash Flow - TradingKey
Neuphoria Therapeutics Market Sentiment - Benzinga España
NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
Monteverde & Associates investigates Neuphoria Therapeutics merger fairness for shareholders. - Pluang
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) - PR Newswire
Neuphoria Therapeutics (NEUP) Proxy filing Summary - Quartr
Neuphoria Therapeutics to Merge with Scancell Holdings - TipRanks
Neuphoria Therapeutics (Nasdaq: NEUP) to be acquired by Scancell - Stock Titan
Neuphoria Therapeutics to Merge With Scancell; Holders to Receive ADSs Plus CVRs - TradingView
Scancell and Neuphoria agree all-share merger supported by up to US$89 million financing - Yahoo Finance UK
NEUPHORIA THERAPEUTICSSCANCELL EXPECTS TO SECURE UP TO $89 MLN IN FINANCING - Moomoo
Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell - Moomoo
Scancell Holdings plc agreed to acquire Neuphoria Therapeutics Inc. for $34.7 million. - marketscreener.com
Scancell, Neuphoria Therapeutics Agree All-share Merger - Moomoo
Scancell merges with Neuphoria after Merck axes trial; AstraZeneca breast cancer drug approved in EU - Endpoints News
Scancell agrees to buy Neuphoria, combined firm set to list on Nasdaq - marketscreener.com
Neuphoria Therapeutics Inc (NEUP) 財務データ
収益
当期純利益
現金流量
EPS
1.29%
0.24%
大文字化:
|
ボリューム (24 時間):